Furthermore, the authors reported that a naked, unmodified novel RNAi agent, such as ribophorin II (RPN2-PnkRNA), used as a therapeutic target for lung cancer, plays a key role in the inhibition of tumour growth without any significant toxicity [68]. This evidence concerns the gene RPN2 and lung cancer.